May 21, 2021 / 04:00PM GMT
Philip M. Nadeau - Cowen and Company, LLC, Research Division - MD & Senior Research Analyst
Good afternoon, and welcome once again to Cowen and Company's Second Annual Oncology Innovation Summit. I'm Phil Nadeau, one of the biotech analysts here at Cowen, and it's my pleasure to moderate a fireside chat with Gilead Sciences. We're really happy to have with us today, Merdad Parsey, the Chief Medical Officer of Gilead.
Merdad, thanks so much for joining us. I'm sure these are incredibly busy times for you.
Merdad V. Parsey - Gilead Sciences, Inc. - Chief Medical Officer
I really appreciate the invite, Phil. Good to see you. Thanks.
Questions and Answers:
Philip M. Nadeau - Cowen and Company, LLC, Research Division - MD & Senior Research AnalystI think we'll focus today's discussion specifically on your oncology pipeline in light of ASCO and EHA coming up. Maybe first, we'll start with Trodelvy. There's a vigorous debate on the Street about Trodelvy's TROPiCS-02 trial and ER-positive HER2
Trustpilot
